FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029122528> ?p ?o ?g. }

• W2029122528 endingPage "135" @default.
• W2029122528 startingPage "121" @default.
• W2029122528 abstract "Background Adaptive dose-ranging trials are more efficient than traditional approaches and may be designed to explicitly address the goals and decisions inherent in learn-phase drug development. We report the design, implementation, and outcome of an innovative Bayesian, response-adaptive, dose-ranging trial of an investigational drug in patients with diabetes, incorporating a dose expansion approach to flexibly address both efficacy and safety. Purpose The design was developed to assess whether one or more doses of an investigational drug demonstrated superior efficacy to an active control while maintaining an acceptable safety profile. Methods The trial used a two-stage design, in which patients were initially allocated equally to placebo, investigational drug at a low and a medium dose, and an active control. Movement to the second stage was contingent upon evidence of efficacy (measured by change in fasting blood glucose) to add a very low dose of the investigational drug and of safety (measured by weight gain) to add a high dose of the investigational drug. The design incorporated a longitudinal model to maximize use of incomplete data, predictive probabilities to guide the decisions to terminate the trial for futility or move on to Stage 2, and a dose-response model in Stage 2 to borrow information across adjacent doses. Extensive simulations were used to fine tune trial parameters, to define operating characteristics, and to determine the required sample sizes. A data monitoring committee was provided with frequent reports to aid in trial oversight. Results In Stage 1, as trial data accrued, the predictive probability that either the low or medium dose of the investigational drug was superior to the active control fell to low values. Stage 1 termination was recommended after 199 subjects were randomized, out of a maximum trial size of 500 subjects, and the final sample size was 218. Thus the trial did not progress to Stage 2. Limitations Because of the relatively narrow dose range to be assessed, and the inability to utilize the highest dose at the beginning of the trial, a fully responsive-adaptive design incorporating dose-response modeling was not considered a viable option. This limited the efficiency gains possible with a full set of adaptive design elements. Conclusions The two-stage dose-expansion design functioned as designed, recommending early termination based on a low probability that the tested doses had efficacy greater than the active control. Clinical Trials 2010; 7: 121—135. http://ctj.sagepub.com" @default.
• W2029122528 created "2016-06-24" @default.
• W2029122528 creator A5000299088 @default.
• W2029122528 creator A5008804272 @default.
• W2029122528 creator A5016743321 @default.
• W2029122528 creator A5021959578 @default.
• W2029122528 creator A5028472576 @default.
• W2029122528 creator A5060618362 @default.
• W2029122528 creator A5073571977 @default.
• W2029122528 creator A5090021604 @default.
• W2029122528 date "2010-03-25" @default.
• W2029122528 modified "2023-10-11" @default.
• W2029122528 title "A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug" @default.
• W2029122528 cites W157796586 @default.
• W2029122528 cites W1895993106 @default.
• W2029122528 cites W1926357153 @default.
• W2029122528 cites W1973002971 @default.
• W2029122528 cites W1998123344 @default.
• W2029122528 cites W2025608337 @default.
• W2029122528 cites W2051068268 @default.
• W2029122528 cites W2054344599 @default.
• W2029122528 cites W2093423617 @default.
• W2029122528 cites W2096940309 @default.
• W2029122528 cites W2100637077 @default.
• W2029122528 cites W2129546350 @default.
• W2029122528 cites W2143548516 @default.
• W2029122528 cites W2167228337 @default.
• W2029122528 cites W2315885933 @default.
• W2029122528 cites W2512907691 @default.
• W2029122528 doi "https://doi.org/10.1177/1740774510361541" @default.
• W2029122528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20338905" @default.
• W2029122528 hasPublicationYear "2010" @default.
• W2029122528 type Work @default.
• W2029122528 sameAs 2029122528 @default.
• W2029122528 citedByCount "37" @default.
• W2029122528 countsByYear W20291225282012 @default.
• W2029122528 countsByYear W20291225282013 @default.
• W2029122528 countsByYear W20291225282014 @default.
• W2029122528 countsByYear W20291225282015 @default.
• W2029122528 countsByYear W20291225282016 @default.
• W2029122528 countsByYear W20291225282017 @default.
• W2029122528 countsByYear W20291225282018 @default.
• W2029122528 countsByYear W20291225282019 @default.
• W2029122528 countsByYear W20291225282022 @default.
• W2029122528 countsByYear W20291225282023 @default.
• W2029122528 crossrefType "journal-article" @default.
• W2029122528 hasAuthorship W2029122528A5000299088 @default.
• W2029122528 hasAuthorship W2029122528A5008804272 @default.
• W2029122528 hasAuthorship W2029122528A5016743321 @default.
• W2029122528 hasAuthorship W2029122528A5021959578 @default.
• W2029122528 hasAuthorship W2029122528A5028472576 @default.
• W2029122528 hasAuthorship W2029122528A5060618362 @default.
• W2029122528 hasAuthorship W2029122528A5073571977 @default.
• W2029122528 hasAuthorship W2029122528A5090021604 @default.
• W2029122528 hasConcept C126322002 @default.
• W2029122528 hasConcept C19527891 @default.
• W2029122528 hasConcept C2780035454 @default.
• W2029122528 hasConcept C41008148 @default.
• W2029122528 hasConcept C535046627 @default.
• W2029122528 hasConcept C71924100 @default.
• W2029122528 hasConcept C73751289 @default.
• W2029122528 hasConcept C98274493 @default.
• W2029122528 hasConceptScore W2029122528C126322002 @default.
• W2029122528 hasConceptScore W2029122528C19527891 @default.
• W2029122528 hasConceptScore W2029122528C2780035454 @default.
• W2029122528 hasConceptScore W2029122528C41008148 @default.
• W2029122528 hasConceptScore W2029122528C535046627 @default.
• W2029122528 hasConceptScore W2029122528C71924100 @default.
• W2029122528 hasConceptScore W2029122528C73751289 @default.
• W2029122528 hasConceptScore W2029122528C98274493 @default.
• W2029122528 hasIssue "2" @default.
• W2029122528 hasLocation W20291225281 @default.
• W2029122528 hasLocation W20291225282 @default.
• W2029122528 hasOpenAccess W2029122528 @default.
• W2029122528 hasPrimaryLocation W20291225281 @default.
• W2029122528 hasRelatedWork W2051359673 @default.
• W2029122528 hasRelatedWork W2081457677 @default.
• W2029122528 hasRelatedWork W2089805696 @default.
• W2029122528 hasRelatedWork W2561845612 @default.
• W2029122528 hasRelatedWork W2748952813 @default.
• W2029122528 hasRelatedWork W2899084033 @default.
• W2029122528 hasRelatedWork W3110364326 @default.
• W2029122528 hasRelatedWork W3164062608 @default.
• W2029122528 hasRelatedWork W4304688565 @default.
• W2029122528 hasRelatedWork W3086197225 @default.
• W2029122528 hasVolume "7" @default.
• W2029122528 isParatext "false" @default.
• W2029122528 isRetracted "false" @default.
• W2029122528 magId "2029122528" @default.
• W2029122528 workType "article" @default.